Zobrazeno 1 - 5
of 5
pro vyhledávání: '"inhibidores de proteína cinasas"'
Autor:
Carmela Rodríguez-López, Patricia Mondelo-Macía, Teresa Curiel, Antònia Obrador-Hevia, Laura Muinelo-Romay, Laura Valiña, Silvia Calabuig-Fariñas, Roberto Díaz-Peña, Rafael López-López, Angel Diaz-Lagares, Aitor Azkárate, Óscar Rapado-González, María Mercedes Suárez-Cunqueiro, Luis León-Mateos, Ihab Abdulkader, Alicia Abalo, Jorge García-González, Santiago Aguín
Publikováno v:
Cells
Minerva: Repositorio Institucional de la Universidad de Santiago de Compostela
Universidad de Santiago de Compostela (USC)
Volume 9
Issue 2
Cells, Vol 9, Iss 2, p 522 (2020)
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
Minerva: Repositorio Institucional de la Universidad de Santiago de Compostela
Universidad de Santiago de Compostela (USC)
Volume 9
Issue 2
Cells, Vol 9, Iss 2, p 522 (2020)
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d367062e721ab112698a9f41af77633b
http://europepmc.org/articles/PMC7072825
http://europepmc.org/articles/PMC7072825
Autor:
Martín Galache, María
Publikováno v:
GREDOS. Repositorio Institucional de la Universidad de Salamanca
Fundacion Sancho el Sabio Fundazioa (FSS)
Fundacion Sancho el Sabio Fundazioa (FSS)
Trabajo de fin de grado. Grado en Medicina. Curso académico 2019-2020
Los inhibidores de la tirosina cinasa (ITC) constituyen el tratamiento de elección para los pacientes diagnosticados de leucemia mieloide crónica (LMC) en fase crónica, y
Los inhibidores de la tirosina cinasa (ITC) constituyen el tratamiento de elección para los pacientes diagnosticados de leucemia mieloide crónica (LMC) en fase crónica, y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6e813b59c9b4db7aa4d04e145a69e798
https://hdl.handle.net/10366/148310
https://hdl.handle.net/10366/148310
Autor:
Ana Sanches Silva, Seyed Fazel Nabavi, Ammad Ahmad Farooqi, Andrei Mocan, Sundas Fayyaz, Seyed Mohammad Nabavi, Antoni Sureda, Anupam Bishayee
Publikováno v:
Molecules, Vol 22, Iss 5, p 705 (2017)
Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry
Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry
Cancer comprises a collection of related diseases characterized by the existence of altered cellular pathways resulting in an abnormal tendency for uncontrolled growth. A broad spectrum, coordinated, and personalized approach focused on targeting div
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d46434856f5c5febc5f3131a558098b
https://doi.org/10.3390/molecules22050705
https://doi.org/10.3390/molecules22050705
PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation
Autor:
Rayman Choo-Wing, John M. Asara, Dimitrios Anastasiou, Mark J. Arends, Gelareh Zadeh, Adamo Valle, Nikos Koundouros, Yuxiang Zheng, George Poulogiannis, Amit Gupta, Lewis C. Cantley, Yu-Hsin Chiu, Maria Dimitriadi, Sara Anjomani-Virmouni, Sameer Agnihotri
Publikováno v:
Gupta, A, Anjomani-Virmouni, S, Koundouros, N, Dimitriadi, M, Choo-Wing, R, Valle, A, Zheng, Y, Chiu, Y-H, Agnihotri, S, Zadeh, G, Wagner, M, M. Asara, J, Anastasiou, D, Arends, M J, Cantley, L C & Poulogiannis, G 2017, ' PARK2 depletion connects energy and oxidative stress to PI3K/Akt activation via PTEN S-nitrosylation ', Molecular Cell, vol. 65, no. 6, pp. 999-1013.e7 . https://doi.org/10.1016/j.molcel.2017.02.019
PARK2 is a gene implicated in disease states with opposing responses in cell fate determination, yet its contribution in pro-survival signaling is largely unknown. Here we show that PARK2 is altered in over a third of all human cancers, and its deple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8382cb9e16caada1493c79977d1b5ea
https://doi.org/10.1016/j.molcel.2017.02.019
https://doi.org/10.1016/j.molcel.2017.02.019
Autor:
M. Cobo, Alan Webster, Tudor Ciuleanu, Gyula Ostoros, Tsveta Milenkova, Rose McCormack, Jean-Yves Douillard
Publikováno v:
British Journal of Cancer
BACKGROUND: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal growth factor receptor (EGFR) mutation-positive non-small-cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f922773a3293442e06e71cabe3f03c07
https://hdl.handle.net/10668/1847
https://hdl.handle.net/10668/1847